Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Pomalyst led to resolution of anal precancer in men with or without HIV.
Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.
Study finds that routine screening reduces anal cancer rate among people with HIV.
Keytruda may prolong survival compared with standard therapy.
More widespread vaccination could reduce cervical, anal, oral and other cancers caused by human papillomavirus.
Study suggests immune-based cancer therapies might be particularly beneficial for HIV-positive people.
Abnormal anal screening results are common, but they often do not to lead to invasive cancer.
This malignancy, caused by human papillomavirus (HPV), can be prevented with a vaccine.
The vaccine is safe and effective against cancer-causing strains of HPV, and yet anti-vaccination misinformation campaigns have taken hold.
Men who have sex with men are at higher risk for the disease, which is driven by human papillomavirus.
Bloody stools can be a sign of cancer, but not always.
Half of adolescents remain unprotected against virus that causes anal, cervical and oral cancer.
Having both chlamydia and high-risk HPV16 dramatically increases the risk of anal precancer.
Widespread vaccination could potentially eliminate cervical, anal, oral and other HPV-related cancers.
People living with HIV are also facing cancer as they age.
The Office of HIV and AIDS Malignancy at the National Cancer Institute coordinates cancer and HIV research.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.